Authors:
Monali Tayade, Shishanka Wangnoo
Download free PDF
Software as a Medical Device (SaMD) Market Size & Share 2026-2035
Report ID: GMI16467
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Software as a Medical Device (SaMD) Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Software as a Medical Device (SaMD) Size
The global software as a medical device (SaMD) market was valued at USD 5.8 billion in 2025 and is projected to grow from USD 6.5 billion in 2026 to USD 21.1 billion by 2035, expanding at a CAGR of 13.9%, according to the latest report published by Global Market Insights Inc.
Software as a Medical Device (SaMD) Market Key Takeaways
Market Leader: GE HealthCare led with over 22% market share in 2025.
Leading Players: Top 5 players in this market include GE HealthCare, Siemens Healthineers, Koninklijke Philips, iRhythm Technologies, Tempus AI, which collectively held a market share of 58% in 2025.
Software as a Medical Device (SaMD) comprises software intended to diagnose, monitor, prevent, predict, or treat disease while performing its medical function independently of a dedicated hardware medical device. Historical growth of 12.3% during 2022-2024 reflects a transition from isolated digital-health tools toward clinically embedded software connected to electronic health records, imaging archives, connected devices, and care-management workflows.
The installed digital foundation is especially important because SaMD adoption depends less on software availability than on access to usable clinical data and workflow integration. More than 99% of U.S. non-federal acute-care hospitals had adopted certified electronic health records by 2024, while 91% of office-based physicians used certified EHR technology [1]HHS Office of the National Coordinator for Health Information Technology, National Trends in Hospital and Physician Adoption of Electronic Health Records 2024, healthit.gov. This infrastructure lowers the integration barrier for clinical decision support (CDS), imaging algorithms, and remote monitoring platforms, but also raises expectations for interoperability, auditability, and cybersecurity.
AI-enabled SaMD is expanding the addressable use case from record digitization to clinical interpretation. In a multicenter study of 31,141 patients across 23 sites, an AI algorithm for severe aortic stenosis achieved 82.2% sensitivity, 98.1% specificity, and a c-statistic of 0.986 [2]JACC: Advances, An Artificial Intelligence Algorithm for Detection of Severe Aortic Stenosis 2024, jacc.org. In coronary artery calcium scoring, an AI tool produced close agreement with radiologists while reducing interpretation time from 45 seconds to 15 seconds. Such performance matters commercially when it fits a constrained workflow: providers can justify adoption through faster triage, more consistent reading, or a higher likelihood that clinically meaningful abnormalities reach the right specialist.
GMI Analyst View
The market's expansion is being governed by a shift in where clinical value is created. Earlier digital-health adoption focused on capturing and transmitting information; SaMD increasingly converts imaging, physiological signals, and longitudinal records into decisions that can alter triage, diagnosis, treatment selection, or follow-up. That transition supports sustained growth, but it also narrows the field of viable suppliers to those that can demonstrate clinical performance, integrate with incumbent systems, and maintain controlled software changes.
The 13.92% projected growth rate therefore should not be interpreted as uniform demand across all software. Revenue is likely to concentrate in products that shorten a diagnostic or care-management bottleneck and can be reimbursed, embedded in a workflow, or scaled through enterprise infrastructure. Products that rely on standalone clinician behavior change, incomplete data feeds, or unproven clinical benefit face a materially slower route to adoption despite the broader digital-health tailwind.
Key Drivers
Rising adoption of digital health technologies
Digital-health adoption is creating the operating environment in which SaMD can move from a departmental tool to an enterprise clinical capability. Certified EHR use across U.S. hospitals and physician practices provides the patient data, authentication pathways, and workflow touchpoints needed to introduce decision support without requiring clinicians to operate a separate system. The commercial implication is strongest for vendors that can insert recommendations, images, or alerts into existing clinical applications rather than asking providers to build parallel processes.
India illustrates how national infrastructure can widen the future deployment base. The Ayushman Bharat Digital Mission had registered 643,639 healthcare facilities, 523,639 healthcare professionals, and linked 437.9 million health records as of November 2024. Large-scale record linkage does not by itself validate an algorithm, but it improves the potential availability of longitudinal data for population screening, chronic-care monitoring, and locally trained clinical decision tools.
Expansion of remote patient monitoring reimbursement codes
RPM reimbursement has converted a portion of remote monitoring from an innovation project into a billable care-delivery model. CMS covers RPM through codes including 99091, 99453, 99454, 99457, and 99458, while remote therapeutic monitoring codes introduced in 2022 broadened billing to therapeutic devices and treatment-management workflows [3]Centers for Medicare & Medicaid Services, Remote Patient Monitoring 2024, cms.gov. Reimbursement can accelerate software adoption because it links the cost of patient onboarding, device data collection, and clinician time to a defined payment pathway.
The effect is not automatically positive for every RPM platform. HHS OIG has identified growing RPM billing utilization across Medicare fee-for-service and Medicare Advantage, making documentation, patient eligibility, and service delivery increasingly important to provider economics. Suppliers that provide auditable data capture and workflow support are better positioned than vendors offering device dashboards without a credible path to clinical staffing and billing compliance.
AI-powered diagnostic SaMD demonstrating superior clinical sensitivity in comparison with traditional methods
Diagnostic SaMD gains traction when it improves detection or reduces variation in a task with limited specialist capacity. AI-assisted echocardiographic detection of severe coronary artery disease achieved an area under the curve of 0.93, and clinician use of the tool increased inter-reader sensitivity by 10%. In pathology, PathAI reported that AI assistance improved inter-rater agreement and positive percent agreement among pathologists evaluating ambiguous HER2 thresholds. These findings support adoption where inconsistent interpretation affects downstream testing, treatment selection, or referral.
The economics depend on the point of insertion. An algorithm that identifies an actionable abnormality earlier may reduce missed findings; one that accelerates routine interpretation may release specialist time. The highest-value products will increasingly need to demonstrate both: technical accuracy without measurable workflow benefit is unlikely to justify enterprise purchasing, whereas a clinically integrated tool can be evaluated against staffing pressure, turnaround time, and diagnostic confidence.
Regulatory support for digital therapeutics and software-based solutions
Regulatory and reimbursement frameworks are becoming more tailored to software, though requirements remain stringent. Germany's DiGA pathway can provide statutory health-insurance reimbursement within three months of BfArM approval, and 53 DiGAs had been listed by January 2024, including 29 permanent listings. From September 2020 through September 2023, roughly 374,000 DiGA prescriptions were activated, indicating that software reimbursement can generate real utilization when clinical evidence and market access are aligned [4]Nature npj Digital Medicine, The three-year evolution of Germany's Digital Therapeutics reimbursement framework 2024, nature.com.
Japan is also adapting review processes to software. PMDA reorganized its SaMD office in July 2024 under DASH for SaMD 2, with two review teams intended to support more specialized review. These mechanisms reduce uncertainty around market entry, but they do not eliminate the evidence burden. Vendors still need to align intended use, clinical claims, change-control processes, and local reimbursement requirements before an authorization becomes scalable revenue.
Key Restraints
Cybersecurity and data privacy concerns
SaMD expands the attack surface of healthcare delivery because software may access patient records, imaging data, cloud services, connected devices, and clinician workstations. The U.S. Department of Health and Human Services proposed modifications to the HIPAA Security Rule in December 2024 in response to escalating cyber threats, signaling a higher compliance burden for organizations handling electronic protected health information. For developers, security therefore affects product design, procurement timelines, and post-market obligations rather than functioning as a separate IT issue.
The burden is sharper for cloud-connected and multi-site deployments. Medical-device cybersecurity vulnerabilities have been associated with FDA-reported adverse events, while both FDA expectations and European rules increasingly incorporate cybersecurity into premarket evaluation. Purchasers may favor vendors that can document vulnerability management, access controls, incident response, and update governance; smaller developers without those capabilities can face longer sales cycles even when their clinical algorithms are differentiated.
Challenges in clinical validation and evidence generation
Software changes faster than conventional clinical-study models. A 2024 review of clinical decision support software found that products can change substantially before traditional evidence-generation cycles are completed. This creates a practical tension: developers need iterative improvement to maintain performance and respond to clinical feedback, yet healthcare providers and regulators require evidence that the version being deployed remains safe and effective.
The evidence gap is commercially consequential. An assessment of digital-health technologies found that 44% of startups had a clinical-robustness score of zero, while conventional randomized trials may require more than 5.5 years. Higher-risk products can neither rely on usability evidence alone nor postpone validation until after broad commercialization. Suppliers that build prospective evidence plans, data-governance controls, and disciplined version management early are more likely to shorten procurement friction and preserve credibility as algorithms evolve.
GMI Analyst View
The market is being pulled forward by reimbursement, clinical-performance evidence, and regulatory specialization, but these forces also raise the threshold for durable participation. RPM reimbursement creates a near-term revenue pathway, while diagnostic algorithms can establish value through measurable accuracy or workflow improvement. In both cases, the product must be deployable within the payer, provider, and data-governance conditions that determine whether a clinical capability can be operationalized.
Cybersecurity and validation act as selection mechanisms rather than temporary inconveniences. They favor platforms able to support secure integration, controlled releases, and evidence generation across multiple sites. This is likely to widen the gap between suppliers with enterprise-grade quality systems and software developers whose products remain technically promising but insufficiently validated for high-consequence clinical decisions.
Software as a Medical Device (SaMD) Segment Analysis
Software Type
CDS software generated USD 1,997.55 million in 2025, representing 34.66% of the market, and is forecast to reach USD 7,880.15 million by 2035 at a 14.76% CAGR. Its scale reflects its ability to use patient history, laboratory results, guidelines, and clinical context within routine care decisions. Evidence from an AHRQ systematic review of 33 articles found moderate-strength evidence that computerized CDS can reduce medication errors and prevent adverse drug events [5]Agency for Healthcare Research and Quality, Computerized Clinical Decision Support To Prevent Medication Errors 2024, ncbi.nlm.nih.gov. The category's growth depends on whether recommendations are timely and specific enough to improve decisions without adding alert fatigue.
RPM software is projected to expand from USD 756.45 million in 2025 to USD 2,821.67 million by 2035. The segment benefits from reimbursement and chronic-care demand, but its growth is constrained by clinical operations. Data from wearables and connected devices becomes valuable only when providers can triage alerts, engage patients, and document interventions. Huma reported that its RPM offering covered 140,000 contracted lives and was used across more than 3,000 hospitals, illustrating the importance of enterprise contracting and care-network integration in scaling RPM.
Digital therapeutics are expected to rise from USD 622.02 million in 2025 to USD 2,260.88 million by 2035. Their commercial model differs from diagnostic software because clinical efficacy must be paired with prescription behavior, payer acceptance, and sustained patient engagement. Surgical planning and navigation software, valued at USD 527.89 million in 2025, occupies a more specialized but defensible position where planning, segmentation, and navigation can affect procedural precision. Brainlab's Elements platform combines tumor segmentation, fiber tracking, trajectory planning, and distortion correction for cranial procedures. Other software types will remain relevant where narrow clinical workflows support specialized, validated applications.
Deployment Mode
Cloud-based SaMD represented USD 3,712.59 million, or 64.41% of 2025 revenue, and is projected to grow at 14.34% CAGR through 2035. Its attraction lies in centralized deployment, multi-site access, and the ability to maintain consistent versions across distributed care settings. Philips cited provider expectations that 95% of healthcare organizations will migrate at least half of their applications to the cloud within three years, and its HealthSuite Imaging model is positioned as software-as-a-service for enterprise imaging workflows [7]Philips, Philips expands cloud-based enterprise imaging services to Europe 2025, philips.com.
Cloud adoption does not remove data-control concerns; it transfers them into vendor qualification, architecture, and contractual governance. On-premise deployments held USD 2,051.48 million in 2025 and will continue to serve institutions with stringent local-data requirements, complex legacy environments, or highly customized workflows. The market is therefore likely to retain a hybrid deployment mix, with cloud favoring scalable enterprise applications and on-premise solutions remaining relevant where control, latency, or local integration constraints outweigh the benefit of centralized updates.
IMDRF Risk Category
Category II software held the largest share at 45.42% in 2025, equivalent to USD 2,617.94 million. This category includes many moderate-risk monitoring, assessment, and decision-support applications, making it the practical center of current SaMD commercialization. Category III software, valued at USD 1,693.68 million in 2025, is projected to grow at 14.18% CAGR as advanced diagnostics and specialized disease-management tools address higher-consequence decisions.
The faster forecast growth in Category IV, at 14.57%, signals greater value creation in software with more consequential clinical roles, but that value comes with a higher proof burden. Under EU MDR Rule 11, many medical software products are classified as Class IIa or higher and require notified-body involvement and enhanced clinical evidence. Risk classification thus influences not only authorization requirements but also capital needs, launch timing, and the attractiveness of post-market change-control pathways.
End Use
Hospitals and clinics generated USD 2,772.45 million in 2025, accounting for 48.10% of market revenue. Their scale derives from the concentration of imaging, acute-care decision making, specialist capacity, and EHR infrastructure. Enterprise purchasers will increasingly assess SaMD through operational outcomes: whether a solution reduces reporting turnaround, improves referral prioritization, supports staffing constraints, or improves care coordination across departments.
Diagnostic and radiology centers are forecast to grow at 14.43% CAGR, supported by automated image analysis, reporting workflows, and the need to manage expanding imaging volumes. Home care settings are expected to post the fastest end-use growth at 15.01% CAGR, reaching USD 3,300.63 million by 2035. This trajectory is tied to RPM and chronic-disease care models, where software can connect patients, devices, and care teams outside formal facilities. Research and academic institutions remain important for algorithm validation and translational deployment, while other end users support narrower applications in specialty and distributed-care environments.
GMI Analyst View
The segment mix shows that the most valuable SaMD is not defined solely by its algorithm. CDS leads because it can be applied across broad clinical workflows, whereas diagnostic imaging software benefits from structured data and established specialist use cases. RPM and home care settings are growing faster because they extend care beyond the facility, but their economics are contingent on reimbursement, patient adherence, and a provider's capacity to act on incoming data.
Risk and deployment choices will increasingly shape supplier strategy. Cloud delivery provides a route to enterprise scale and managed updates, yet higher-risk applications require more rigorous evidence and change control. Suppliers that align clinical claims, risk classification, deployment architecture, and operating workflow from the outset will be better positioned than those attempting to retrofit governance after product adoption begins.
Software as a Medical Device (SaMD) Regional Analysis
North America
North America generated USD 2,307.12 million in 2025, or 40.03% of global revenue, and is projected to reach USD 7,895.30 million by 2035. The U.S. represented 94.45% of the regional market, valued at USD 2,176.95 million in 2025, while Canada accounted for USD 130.17 million. Regional leadership rests on EHR penetration, reimbursed RPM pathways, a large base of regulated digital-health suppliers, and deep imaging infrastructure. The U.S. advantage is reinforced by the ability of FDA-cleared products to access large integrated delivery networks, although cybersecurity scrutiny and fragmented procurement can lengthen enterprise sales cycles.
Europe
Europe accounted for USD 1,618.64 million in 2025 and is forecast to grow at 13.44% CAGR. Germany is particularly influential because DiGA connects regulatory qualification to statutory reimbursement, while the wider region presents a more demanding compliance environment for medical software under MDR. European suppliers and entrants must therefore balance the opportunity for reimbursed digital therapeutics and enterprise imaging with notified-body requirements, privacy expectations, and cross-border interoperability constraints.
Asia Pacific
Asia Pacific is expected to be the fastest-growing region, rising from USD 1,307.68 million in 2025 to USD 5,440.87 million by 2035 at a 15.37% CAGR. Japan's dedicated SaMD review capabilities and India's digital-health infrastructure illustrate two different growth mechanisms: one lowers regulatory specialization barriers, while the other expands the underlying data and care-delivery network. India has also designated AI centers of excellence and deployed AI-enabled clinical decision support within eSanjeevani, supporting the local institutional base for AI-assisted care. China, South Korea, Australia, and Japan add demand through advanced diagnostics, digital-health investment, and specialist-care modernization.
Latin America
Latin America generated USD 309.65 million in 2025 and is projected to reach USD 1,227.38 million by 2035. Brazil is a key regional anchor because ANVISA has established a SaMD framework through RDC No. 657/2022 and RDC No. 751/2022, while its 2024-2025 agenda includes work on cybersecurity requirements for SaMD [8]Emergo by UL, Brazil ANVISA Announces Priorities for the 2024-2025 Year 2024, emergobyul.com. This supports more predictable market access, but localized reimbursement, provider budget constraints, and deployment capacity will determine whether digital diagnostics and remote monitoring can move beyond major urban health systems.
Middle East and Africa
The Middle East and Africa market was valued at USD 220.97 million in 2025 and is forecast to grow at 14.62% CAGR. Saudi Arabia's medical-software-developer licensing initiative, launched in October 2024, established a pathway for digital-health software deployment without physical manufacturing facilities. The UAE is also building institutional demand through AI-enabled health initiatives, including an emergency-operations dashboard and the Biosigns AI vital-signs tool. Demand in Saudi Arabia, the UAE, and South Africa will be shaped by government-led digital-health programs, hospital modernization, and the ability of suppliers to support local data, procurement, and clinical-governance requirements.
GMI Analyst View
Regional growth is being determined by different combinations of reimbursement, regulation, digital infrastructure, and provider readiness. North America remains the revenue center because these elements are already connected through enterprise providers and defined payment pathways. Europe offers structured access for eligible digital therapies but imposes a more formal evidentiary and classification burden. Asia Pacific's faster trajectory reflects the expansion of enabling infrastructure and specialized regulatory capacity rather than a single uniform market condition.
For suppliers, geographic expansion should not be sequenced solely by market size. A reimbursed pathway in Germany, a specialist review route in Japan, and a national health-data infrastructure buildout in India each require different evidence, integration, and commercialization models. Companies that treat regional market entry as a regulatory filing exercise alone risk underestimating the local operational requirements needed to translate authorization into sustained use.
Software as a Medical Device (SaMD) Share & Competitive Landscape
Competition is centered on clinical validation, regulatory clearance, workflow integration, cybersecurity, and the ability to operate at enterprise scale. Aidoc Medical, Brainlab AG, Butterfly Network, Canon Medical Systems, Fujifilm Holdings, GE HealthCare, Huma Therapeutics, iRhythm Technologies, Koninklijke Philips, Medtronic, PathAI, Qlarity Imaging, Roche Diagnostics, Siemens Healthineers, Tempus AI, and Viz.ai comprise the approved company scope.
Imaging-platform suppliers are competing to make algorithms deployable across existing clinical systems. Fujifilm's Synapse AI Orchestrator offers more than 50 validated imaging algorithms within its PACS environment and supports cloud-based or on-premise deployment. Roche's navify Digital Pathology supports cloud and on-premise enterprise pathology workflows and incorporates more than 20 algorithms from Roche and third-party developers. These platforms compete not only through proprietary algorithms, but through their capacity to reduce the integration burden of managing a multi-vendor clinical AI portfolio.
Clinical-specialty suppliers differentiate through focused evidence and regulated use cases. Viz.ai's platform had been deployed at more than 1,500 hospitals in the U.S. and Europe when it received FDA clearance for intracerebral hemorrhage quantification in February 2024 [9]Viz.ai, Viz.ai Receives FDA 510(k) Clearance for AI Algorithm for Quantification of Intracerebral Hemorrhage February 8 2024, viz.ai. Qlarity Imaging's QuantX breast MRI biopsy-guidance software received FDA 510(k) clearance as a Class II AI-powered image-processing application. In cardiac monitoring, Medtronic's LINQ II uses AccuRhythm AI to reduce false alerts while retaining true alerts for atrial fibrillation and pause detection. These applications illustrate the competitive value of a narrow clinical claim supported by workflow relevance.
Scale is also being built through partnerships, cloud infrastructure, and data access. Philips expanded its HealthSuite cloud collaboration in 2024 to support imaging, digital pathology, cardiology, and AI-enabled visualization workflows. GE HealthCare has pursued healthcare-specific generative-AI and cloud-imaging integration through its strategic collaboration with AWS. Tempus AI's clinical-data and precision-medicine position is supported by its agreement to distribute Median Technologies' eyonis LCS lung-cancer-screening SaMD through the Tempus Pixel platform in the United States. These arrangements can improve distribution and interoperability, but successful commercialization still depends on clinical validation and provider workflow adoption.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →